A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.32 enrolled

Overview

The purpose of this study is to evaluate the safety and effectiveness of JNJ-31001074 compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD).

This study is being done to assess safety and tolerability and to explore the effectiveness of a new, experimental drug in the treatment of attention deficit hyperactivity disorder in adults. Approximately 144 adult patients with ADHD will be recruited for the study. Patients who meet study criteria will need to stop taking any ADHD medications they are currently using. They will be randomly assigned to one of 3 treatment arms; each patient has an equal chance of receiving 10 mg JNJ-31001017, 30 mg JNJ-31001074, or placebo. Placebo has no active drug. This is a blinded study, i.e. the patient, the study doctor and the study sponsor will not know what treatment the patient receives until all patients complete the study. Patients will be dispensed a bottle containing study drug for the upcoming week at 4 of the study visits. The study doctor and the sponsor will monitor the study for the occurrence of possible side effects. In addition to a screening visit, patients will return weekly for 6 additional study visits including an end of study visit and a follow-up visit. Patients will take study drug for a total of 4 weeks. After completing the study, patients may resume other ADHD medications. Medical and ADHD history, physical examination, blood pressure, heart rate, temperature, weight and ECGs will be checked periodically throughout the study. Blood samples will be taken for standard safety laboratory tests as well as for the measurement of the drug blood level. Questionnaires relating to ADHD and cognitive testing will be administered throughout the study. Each day for four weeks, patients will take orally, at least one hour before eating in the morning, 1 tablet containing either 10 mg JNJ-31001074, 30 mg JNJ-31001074 or placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

PlaceboDRUG

one dose daily for 4 weeks

JNJ-31001074DRUG

10 mg daily for 4 weeks

JNJ-31001074DRUG

30 mg daily for 4 weeks

Eligibility

Sex: MALEMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of attention deficit hyperactivity disorder with symptoms from age 7 * In good general health * Willing to not take any other ADHD medication or start any behaviorial modification programs during the study * Willing to use approved birth control throughout the study and for 3 months afterwards Exclusion Criteria: * Any psychiatric condition including acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder (OCD), anti-social personality disorder or borderline personality disorder * Autism, asperger's syndrome, mental retardation * Presence of motor tics, history of Tourette's syndrome or family history of Tourette's syndrome * History of substance use/abuse disorder or eating disorder * History of myocardial infarction, stroke, glaucoma, seizures, hypertension, heart rhythm abnormalities or color blindness * Use of prescription medication or herbal supplements

Locations (21)

Unnamed facility

Irvine, California, United States

Unnamed facility

Lafayette, California, United States

Unnamed facility

Outcomes

Primary Outcomes

The primary study objective is to evaluate the safety and effectiveness of JNJ- 31001074 in adult patients with ADHD.

Time frame: ADHD assessments, vital signs, laboratory tests and ECGs will be collected 7 times during the study; at screening, baseline and 5 weekly visit. Adverse events will be collected throughout the study.

Secondary Outcomes

The secondary study objective is to assess drug levels in adults with ADHD after taking JNJ-31001074.

Time frame: Samples to measure drug levels in the blood will be collected three times at baseline and termination visits and once at visits done at Weeks 1, 2, and 3.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.